Staidson: Announcement on changes in the company's pharmaceutical production license
Shu Taishen: An indicative announcement on the disclosure of the report for the first quarter of 2024
Shu Taishen: Report for the first quarter of 2024
Shu Taishen: Investor Relations Activity Record Form (2023 Annual Results Online Briefing)
Shu Taishen: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Shu Taishen: Legal Opinion of Beijing Kangda Law Firm on the 2023 Annual General Meeting of Shareholders of Shu Taishen (Beijing) Biopharmaceutical Co., Ltd.
Shu Taishen: Notice on acceptance of the application for clinical trials of STSP-0902 eye drops (used to treat neurotrophic keratitis) as a new drug
Shu Taishen: Announcement on acceptance of the STSP-0902 injection (used to treat oligospermia) clinical trial application for a new drug
Shu Taishen: Prompt Announcement on Convening the 2023 Annual General Meeting of Shareholders
Shu Taishen: Announcement on shareholders holding 5% or more of their shares without reducing their holdings at the end of the term of the holdings reduction plan
Shu Taishen: Internal Control Verification Report
Shu Taishen: Independent Director Mr. Zhao Jiajun's 2023 Debriefing Report
Shu Taishen: 2023 Annual Report
Shu Taishen: Announcement on Preparation for Asset Impairment and Asset Write-off
Shu Taishen: Independent Director Mr. Zhao Li's 2023 Debriefing Report
Shu Taishen: Announcement on the Company's Renewal of the Accounting Firm
Shu Taishen: 2023 Internal Control Self-Evaluation and Related Opinions Announcement
Shu Taishen: 2023 Operating Income Deduction Review Report
Shu Taishen: Guojin Securities Co., Ltd.'s special inspection opinion on the storage and use of funds raised by Shu Taishen (Beijing) Biopharmaceutical Co., Ltd. in 2023
Shu Taishen: 2023 Annual Report Summary
No Data